Talzenna Capsule, Liquid Filled
NDC 63539-025
Product Information
Talzenna (talazoparib) is a NDA-approved product labeled by U.s. Pharmaceuticals. This medication is used to treat breast cancer. It is supplied as a orange capsule, liquid filled for oral administration. This product entry covers the primary NDC 63539-025 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
TLZ;050
Code Structure Chart
Product Details
What is NDC 63539-025?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TALAZOPARIB TOSYLATE (UNII: 02WK9U5NZC)
- TALAZOPARIB (UNII: 9QHX048FRV) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)
- GLYCERIN (UNII: PDC6A3C0OX)
- GELATIN TYPE A PORCINE (195 BLOOM) (UNII: 6EG4DCS5TJ)
- SORBITOL (UNII: 506T60A25R)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- WATER (UNII: 059QF0KO0R)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2099954 - talazoparib 1 MG Oral Capsule
- RxCUI: 2099954 - talazoparib 1 MG (as talazoparib tosylate 1.453 MG) Oral Capsule
- RxCUI: 2099956 - Talzenna 1 MG Oral Capsule
- RxCUI: 2099956 - talazoparib 1 MG Oral Capsule [Talzenna]
- RxCUI: 2099956 - Talzenna 1 MG (as talazoparib tosylate 1.453 MG) Oral Capsule
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.